Table 3.
Potential therapeutic strategy for CVDs.
| Reagents | Function | Diseases | References |
|---|---|---|---|
| Fer-1 | Blocks lipid peroxidation | DOX-induced cardiomyopathy, Myocardial IRI, AS, Sepsis-induced cardiac injury | (22, 45, 78, 103, 112) |
| DXZ | Prevents lipid peroxidation | DOX-induced cardiomyopathy, Myocardial IRI, Sepsis-induced cardiac injury | (22, 45) |
| Mito TEMPO | Suppress lipid peroxidation | DOX-induced cardiomyopathy, DCM | (22, 83) |
| Lip-1 | Increases GPX4 and reduce ROS | Myocardial IRI | (101) |
| mTOR | Prevents iron overload | Myocardial infarction | (91) |
| Puerarin | Blocks iron overload and lipid peroxidation | Heart failure induced by pressure overload | (108) |
Fer-1, ferrostatin-1; DOX, doxorubicin; IRI, ischemia-reperfusion injury; AS, atherosclerosis; DXZ, dexrazoxane; DCM, diabetic cardiomyopathy; Lip-1, liproxstatin-1; GPX4, glutathione peroxidase 4; ROS, reactive oxygen species.